COFEPRIS Mexico Simplifies Procedures: A New Era for Healthcare Product Registration
In a historic move for the Latin American healthcare sector, COFEPRIS (Mexico) has announced administrative simplification measures to eliminate bureaucratic bottlenecks. As of May 4th, 2026, the entry of health technologies into the country will be accelerated through digital processes and Reliance mechanisms. For GRP Mexico clients, this change is even more advantageous due to our direct presence in the country.
Mexico Strengthens Health Security: The Transition from the CNFV to the New CENAFyT
Mexico has taken a decisive step in modernizing its healthcare system with the creation of the National Center for Pharmacovigilance and Technovigilance (CENAFyT). Integrated into the General Health Law, this new body expands supervisory powers over both medicines and medical equipment, ensuring greater protection for all citizens.
The New period of Regulation in Mexico: Modernization and Sovereignty (2024–2026)
Between 2024 and 2026, Mexico underwent a profound transformation of its regulatory landscape for medicines and vaccines. Led by COFEPRIS, this shift focuses on agility through the “regulatory reliance” model, ensuring that medical innovation reaches patients faster without compromising scientific rigor or national sovereignty.
Brazil Approves New Composition for Seasonal Influenza Vaccines
Annual influenza vaccination is one of the most effective strategies for preventing respiratory complications and reducing hospitalizations caused by the flu virus. Each year, the vaccine composition must be updated based on the most recent circulating strains. In 2025, ANVISA approved a new regulation defining the composition of seasonal influenza vaccines to be used in Brazil, aligning the country with World Health Organization (WHO) recommendations.
Anvisa approves release of vaccine and medicine against monkey pox
Anvisa approves release of vaccine and medicine against monkey pox
Brazil’s Anvisa approves Anvisa regulates the use of self-tests for Covid-19
Brazil’s Anvisa approves resolution establishing requirements for registration, distribution, commercialization, and use of covid-19 self-tests.
Brazil’s Anvisa approves extending the use of CoronaVac to children and adolescents aged 6 to 17 years
The emergency use authorization granted this Thursday (01/20) is valid only for the age group 6 to 17 years old.
Brazil’s Anvisa identifies positive Covid-19 case in Brazilian passenger from South Africa
The Ordinance No.660/2021 It would impose restrictions on exceptional and specific restrictions, measures and requirements for entry into the country, due to the risks of contamination and dissemination of the SARS-CoV-2 coronavirus (covid-19).
Brazil’s Anvisa releases a new Adverse Event Notification Form
Brazil’s Anvisa introduces new tool enables faster and easier notification of drugs and vaccines.
Distribution Process of the Covid-19 vaccines in Brazil
From the lab to the arm: learn about the Ministry of Health’s Covid-19 vaccine trial in Brazil.
FioCruz reinforces the position adopted by Anvisa, EMA and WHO on vaccine safety
Confidentiality agreement between the two regulatory authorities confirms Anvisa’s recognition on the international scene.
Guideline for Importation Process of Vaccines in Brazil
Material organized by Procomex brings description about the vaccine importation process into Brazil.